Is RXL a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

116 people get RXL articles and Market Currents by email alert.

Get email alerts on RXL »

HEADLINES:

How To Avoid The Worst Sector ETFs
David Trainer • Wed, Dec 19, 2012 • 15 Comments
The Changing U.S. Demographics Snapshot: Labor Supply Vs. Consumer Demand Shift
Nick Chiu • Wed, Nov 7, 2012 • 8 Comments
Best And Worst ETFs And Mutual Funds: Healthcare Sector
David Trainer • Wed, Oct 24, 2012 • 5 Comments
Healthcare ETFs Look To Supreme Court Ruling
Tom Lydon • Wed, Nov 16, 2011
ETFs For A Healthy Portfolio
Wall Street Sector Selector • Mon, Nov 14, 2011 • 2 Comments
A Strategy For Shorting Leveraged ETF Pairs
Eric Falkenstein • Mon, Oct 31, 2011 • 5 Comments
Best In Class Healthcare And Biotech ETFs
Barchart's ETF Recommendations • Tue, Sep 20, 2011
Leveraged and Inverse ETF Performance YTD
Bespoke Investment Group • Thu, May 26, 2011 • 2 Comments
Identifying Counter Plays for the End of QE2
FocalPoint Analytics • Wed, May 18, 2011 • 276 Comments
REW and RXL: The Paradox of Leveraged ETFs
Spencer Knight • Mon, May 9, 2011 • 1 Comment
Two ETFs for the Boom in Big Pharma
Charles Lewis Sizemore • Fri, Feb 11, 2011 • 10 Comments
Why Health Care ETFs May Be in the Clear
Tom Lydon • Wed, Nov 10, 2010
Best and Worst Performing Leveraged ETFs/ETNs Year to Date
Bespoke Investment Group • Tue, Jun 1, 2010 • 1 Comment
Spice Up Your Portfolio With Leveraged ETFs
Tom Lydon • Sun, May 2, 2010 • 1 Comment
Rydex to Close 12 Leveraged ETFs, Ceding Market Share to ProShares
Ron Rowland • Tue, Apr 27, 2010 • 6 Comments
U.S. Healthcare Reform: Likely a Big Boon for Majority of Healthcare Companies
David Hunkar • Sun, Mar 28, 2010 • 8 Comments
Leveraged ETFs: A Seeking Alpha Expert Panel
SA Editors • Wed, Nov 11, 2009 • 10 Comments
Don Dion: Thoughts on Leveraged ETFs
Don Dion • Wed, Nov 11, 2009
Dave Fry: Thoughts on Leveraged ETFs
David Fry • Wed, Nov 11, 2009 • 9 Comments
Roger Nusbaum: Thoughts on Leveraged ETFs
Roger Nusbaum • Wed, Nov 11, 2009

To learn more about Seeking Alpha Pro, click here.

Leveraged ETFs: A Seeking Alpha Expert Panel
SA Editors • Wed, Nov 11, 2009 • 10 Comments
What Happens When You Hold Leveraged ETFs for More than One Day?
Marc Gerstein • Wed, Mar 25, 2009 • 22 Comments

How To Avoid The Worst Sector ETFs
David Trainer • Wed, Dec 19, 2012 • 15 Comments
The Changing U.S. Demographics Snapshot: Labor Supply Vs. Consumer Demand Shift
Nick Chiu • Wed, Nov 7, 2012 • 8 Comments
Best And Worst ETFs And Mutual Funds: Healthcare Sector
David Trainer • Wed, Oct 24, 2012 • 5 Comments
Healthcare ETFs Look To Supreme Court Ruling
Tom Lydon • Wed, Nov 16, 2011
ETFs For A Healthy Portfolio
Wall Street Sector Selector • Mon, Nov 14, 2011 • 2 Comments
A Strategy For Shorting Leveraged ETF Pairs
Eric Falkenstein • Mon, Oct 31, 2011 • 5 Comments
Best In Class Healthcare And Biotech ETFs
Barchart's ETF Recommendations • Tue, Sep 20, 2011
Leveraged and Inverse ETF Performance YTD
Bespoke Investment Group • Thu, May 26, 2011 • 2 Comments
Identifying Counter Plays for the End of QE2
FocalPoint Analytics • Wed, May 18, 2011 • 276 Comments
REW and RXL: The Paradox of Leveraged ETFs
Spencer Knight • Mon, May 9, 2011 • 1 Comment
Two ETFs for the Boom in Big Pharma
Charles Lewis Sizemore • Fri, Feb 11, 2011 • 10 Comments
Why Health Care ETFs May Be in the Clear
Tom Lydon • Wed, Nov 10, 2010
Best and Worst Performing Leveraged ETFs/ETNs Year to Date
Bespoke Investment Group • Tue, Jun 1, 2010 • 1 Comment
Spice Up Your Portfolio With Leveraged ETFs
Tom Lydon • Sun, May 2, 2010 • 1 Comment
Rydex to Close 12 Leveraged ETFs, Ceding Market Share to ProShares
Ron Rowland • Tue, Apr 27, 2010 • 6 Comments
U.S. Healthcare Reform: Likely a Big Boon for Majority of Healthcare Companies
David Hunkar • Sun, Mar 28, 2010 • 8 Comments
Don Dion: Thoughts on Leveraged ETFs
Don Dion • Wed, Nov 11, 2009
Dave Fry: Thoughts on Leveraged ETFs
David Fry • Wed, Nov 11, 2009 • 9 Comments
Roger Nusbaum: Thoughts on Leveraged ETFs
Roger Nusbaum • Wed, Nov 11, 2009
On the Risks of Using Leveraged ETFs
Russell Bailyn • Tue, Oct 13, 2009

There are no Transcripts on RXL.

Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (Nov 9, 2011)

RXL vs. ETF Alternatives

RXL Description

ProShares Ultra Health Care seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Dow Jones U.S. Health Care IndexSM.
See more details on sponsor's website

Sector: Healthcare

Country: United States

Key Info

In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
Asset Class Performance: Sectors

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 8:13 AM Thomas Lee lifts his year-end S&P 500 (SPY) forecast to 1,715 from 1,580 as the bull has already outrun his expectations. His team sees clues economic performance is picking up, including the outperformance of semiconductors (XSD) vs. transports (IYT), and the steepening of the 10 year/30 year Treasury curve. Risk/reward is particularly appealing in tech (XLK), healthcare (XLV), and financials (XLF). Comment!
Thursday, May 16, 11:42 AM The Dow and S&P 500 are flat, but the Nasdaq gains 0.4% late morning behind a 12.5% jump in Cisco post-earnings and Apple bouncing from the last 2 days' drubbing, up 1.5%. Dragging the Dow is a 2.1% decline in Wal-Mart post-earnings. The notably weak sector today is the year's hottest, healthcare (XLV -0.8%). 1 Comment
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 7:27 AM The S&P 500 (SPY) is fairly valued, says Goldman, but opportunity lies in cyclicals (XLY, XLE, XLI, XLB) which are more undervalued vs. defensives (XLU, XLP, XLV, XTL) than at any time in the last 15 years. "Given the 4 P/E multiple point head start, even a slight valuation normalization should translate into outperformance of cyclicals over defensives during the next 12 months." 1 Comment
Friday, April 26, 8:34 AM The beginning of a bigger move? Two of the year's three strongest performing sectors - healthcare (XLV) and consumer staples (XLP) - are down on the week as the three weakest sectors - energy (XLE), materials (XLB), and tech (XLK) - post gains of 3%-4.5%. 2 Comments
Tuesday, April 2, 1:22 PM Already the best sector YTD, Healthcare widens its lead even further thanks to hikes in Medicaid Advantage rates. The XLV's 17.1% gain is more than 200 bps greater than 2nd place Consumer Staples (XLP), and about 700 bps better than SPY. Getting a relative drubbing are Materials (XLB) and Tech (XLK) - each up less than 4%. Comment!
Friday, March 22, 10:39 AM The health care sector (IYH, XLV) is outperforming the S&P 500 (SPY) through the year's first 11 weeks for the first time in 15 years as companies cut costs and investors bet whatever emanates from D.C. will be good for all involved. "Most of the big drug companies have experienced patent cliffs and are now repositioning themselves for growth," says one fund manager. 2 Comments [Healthcare]
Tuesday, January 8, 6:04 AM Healthcare spending rose at a record low pace of 3.9% to $2.7T in 2011 as patients continued to cut back on medical services amid the economic slump. The growth was the same as in 2010 and 2009, and well below the 8% prior to the financial crisis. However, there are signs the rise in spending could be speeding up again, with expenditure on drugs increasing by 2.9% in 2011 vs 0.4% in 2010, and on doctors' visits by 4.3%. Comment! [Healthcare]
Monday, January 7, 5:33 PM The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents. 2 Comments [Healthcare]
Wednesday, January 2, 9:44 AM The Street's Adam Feuerstein makes 13 biotech stock predictions for 2013, with his number one being that the U.S. launch of Arena Pharmaceuticals' (ARNA) and Eisai's weight-loss pill Belviq "will be a major disappointment." Feuerstein also reckons that Belviq will fail to receive European approval. 17 Comments [Healthcare]
Tuesday, January 1, 6:49 AM The number of drugs that the FDA authorized in 2012 rose to 39 from 30 last year and 21 in 2010, with the figure the highest since 53 in 1996. It also includes 10 medicines with fast-track status. The increase in approvals should help offset the patent cliff, which cost major U.S. and European drug companies $31B in revenues last year. (graph of approvals) Comment! [Healthcare]
Sunday, December 9, 2012, 2:27 AM The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous) 1 Comment [Healthcare, Top Stories]
Monday, November 19, 2012, 10:01 AM President Obama's re-election did not, as some believe, bring an end to the battle over Obamacare, write James Capretta and Yuval Levin in the WSJ. That's because the Administration is reliant on states for two key elements of the the reform: health-insurance exchanges and expanding Medicaid. Some GOP governors have already said "they won't do the federal government's bidding." Capretta and Levin explain why they agree. Comment! [Healthcare]
Saturday, October 6, 2012, 9:00 AM The financial (XLF) and healthcare (XLV) sectors were the big winners this week, both adding to their gains relative to the S&P YTD. Another YTD outperformer, tech (XLK) combined with energy (XLE) to be the weakest sectors this week as both Apple (post-iPhone 5) and oil (post-QE∞) can't shake their hangovers. The defensive utility area (XLU) - which had a big (and worrying to some) run from mid-Spring to mid-Summer - continues to lose ground to the broader market. 3 Comments
Tuesday, October 2, 2012, 9:58 AM Around 12M people will buy $55B worth of health coverage in 2014 via the insurance exchanges being created as part of Obamacare, PWC predicts, adding that the figures could rise to 29M people and $205B respectively by 2021. Most of the money will be new, although some will come from other parts of the market, such as from people whose employers had paid for coverage until now. 1 Comment [Healthcare]
Saturday, August 25, 2012, 10:00 AM Southern Co. (SO) and Verizon (VZ) may be the "poster children" among high dividend-payers as the quest for yield takes the utility (XLU), telecom (IXP), and consumer staples (XLP) sectors to frothy levels. The flip-side are health-care services (XHS), autos (CARZ), housing (IYR), and tech (XLK) - lower payers, but with relative valuations that have rarely been this cheap. 17 Comments [Quick Ideas]

RXL ProShares Ultra Health Care ETF

RXL

ProShares Ultra Health Care ETF